Endocrinology. Ovulation induction with low dose alternate day recombinant follicle stimulating hormone (Puregon)

By Buckler H.M.  

Human Reproduction, Vol. 14, Iss. 12, 1999-12 ,pp. : 2969-2973

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Biological characterization of recombinant human follicle stimulating hormone isoforms

By D'Antonio M.   Borrelli F.   Datola A.   Bucci R.   Mascia M.   Polletta P.   Piscitelli D.  

Human Reproduction, Vol. 14, Iss. 5, 1999-05 ,pp. : 1160-1167

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Recombinant human follicle stimulating hormone versus human menopausal gonadotrophin induction: effects in mature follicle endocrinology

By Teissier M.P.  

Human Reproduction, Vol. 14, Iss. 9, 1999-09 ,pp. : 2236-2241

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon ® ) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation

By Out Henk J.  

Human Reproduction, Vol. 15, Iss. 1, 2000-01 ,pp. : 29-35

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon ® ) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP ® ) in a fixed-dose regimen in women undergoing ovarian stimulation

By Hoomans Eric H.M.  

Human Reproduction, Vol. 14, Iss. 10, 1999-10 ,pp. : 2442-2447

Oxford University Press

Access to resources Recommend Favorite